Form 4: Bristol-Myers Squibb Director Acquires Deferred Share Units

Director Derica W. Rice acquired deferred share units in Bristol-Myers Squibb, convertible to common stock upon ceasing to be a director or at a specified future date.

Summary

• On March 31, 2025, Derica W. Rice, a director of Bristol-Myers Squibb, acquired 614.855 deferred share units.
• These units will convert into shares of common stock upon settlement, which occurs when Rice ceases to be a director or at a future date he previously specified.
• The price per share for the deferred share units is $60.99.
• Following the transaction, Rice beneficially owns 31,296.027 shares, including deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, indicating continued alignment between the director and the company's long-term performance. It's a neutral event with a slightly positive undertone due to the director increasing their stake.

Future Outlook

The deferred share units will be converted into common stock upon settlement, which will occur when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

This filing reflects routine transactions by company insiders, providing transparency into their holdings and alignment with company performance. It's a standard practice for directors to receive and hold deferred share units as part of their compensation.

Stakeholder Impact

• The transaction signals to shareholders that a director is increasing their stake in the company, which can be viewed positively.
• The transaction has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, Bristol-Myers Squibb, Director, Derica W. Rice, Deferred Share Units, Beneficial Ownership, BMY